Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Opportunistic mycoses in COVID-19 patients/survivors: Epidemic inside a pandemic

Haripriya Kuchi Bhotla\textsuperscript{a,3}, Balamuralikrishnan Balasubramanian\textsuperscript{b,1}, Arun Meyyazhagan\textsuperscript{a,c,**}, Karthika Pushpara\textsuperscript{d}, Muruges Easwaran\textsuperscript{e}, Manikantan Pappusamy\textsuperscript{a}, Asivatham Alwin Robert\textsuperscript{f}, Vijaya Anand Arumugam\textsuperscript{g}, Valentina Tsibizova\textsuperscript{h}, Abdullah Msaad Alfalih\textsuperscript{i}, Reem M. Aljowaie\textsuperscript{i}, Muthupandian Saravanan\textsuperscript{j,k,*}, Gian Carlo Di Renzo\textsuperscript{c,**}

\textsuperscript{a} Department of Life Sciences, CHRIST (Deemed to be University), Bengaluru, 560029 Karnataka, India
\textsuperscript{b} Department of Food Science and Biotechnology, College of Life Science, Sejong University, Seoul, 05006, South Korea
\textsuperscript{c} Department of Obstetrics and Gynecology, Centre for Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy
\textsuperscript{d} Department of Zoology, School of Biosciences, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore, 641 043, Tamil Nadu, India
\textsuperscript{e} Computational Biology Lab, Department of Bioinformatics, Bharathiar University, Coimbatore, Tamil Nadu 641 046, India
\textsuperscript{f} Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
\textsuperscript{g} Medical Genetics and Epigenetics Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, 641046, Tamil Nadu, India
\textsuperscript{h} Institute of Perinatology and Pediatrics, Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation
\textsuperscript{i} Department of Botany and Microbiology, College of Science, King Saud University, P.O Box 24552, 11495, Riyadh, Saudi Arabia
\textsuperscript{j} Department of Microbiology and Immunology, Division of Biomedical Sciences, School of Medicine, College of Health Science, Mekelle University, Mekelle, 1871, Ethiopia
\textsuperscript{k} Department of Pharmacology, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha Dental College, 600077, Chennai, Tamil Nadu, India

\textbf{A R T I C L E   I N F O}

Article history:
Received 7 September 2021
Received in revised form 6 October 2021
Accepted 10 October 2021

Keywords:
Intrusive fungus
Immunosuppressed Sepsis
Corticosteroids
COVID-19

\textbf{A B S T R A C T}

Being considered minor vexations, fungal infections hinder the life of about 15% of the world population superficially, with rare threats to life in case of invasive sepsis. A significant rise in the intrusive mycoses due to machiavellian fungal species is observed over the years due to increased pathology and fatality in people battling life-threatening diseases. Individuals undergoing therapy with immune suppressive drugs plus recovering from viral infections have shown to develop fungal sepsis as secondary infections while recovering or after. Currently, the whole world is fighting against the fright of Coronavirus disease (COVID-19), and corticosteroids being the primitive therapeutic to combat the COVID-19 inflammation, leads to an immune-compromised state, thereby allowing the not so harmful fungi to violate the immune barrier and flourish in the host. A wide range of fungal co-infection is observed in the survivors and patients of COVID-19. Fungal species of Candida, Aspergillus and Mucorales, are burdening the lives of COVID-19 patients/survivors in the form of Yellow/Green, White and Black fungus. This is the first article of its kind to assemble note on fungal infections seen in the current human health scenario till date and provides a strong message to the clinicians, researchers and physicians around the world “non-pathological fungal should not be dismissed as contaminants, they can quell immunocompromised hosts”.

© 2021 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.jiph.2021.10.010
1876-0341 © 2021 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding authors.
** Corresponding authors.
E-mail addresses: arun47biotech@gmail.com (A. Meyyazhagan), bioinfosaran@gmail.com (M. Saravanan), giancarlo.direnzo@unipg.it (G.C. Di Renzo).
1 Equal contribution as a first author.
Contents

Introduction ........................................................................................................................................... 1721
First-hand sources ................................................................................................................................. 1721
Usual repressive role of corticosteroids ................................................................................................. 1721
COVID-19 pathogenesis and mode of corticosteroid action ................................................................. 1721
Corticosteroids endorsement for COVID-19 .......................................................................................... 1721
Fungal blooms in severe COVID-19 cases .............................................................................................. 1723
Invasion of the *Mucoarels* ................................................................................................................... 1723
*Candida albicans* pathogenesis ........................................................................................................... 1723
*Aspergillus* species mode of action ..................................................................................................... 1724
Communion of fungus and host ............................................................................................................ 1724
Other persuasive entry routes of fungal spores in COVID patients or survivors ..................................... 1724
Reformed mycobioiune in SARS-CoV-2 infection .................................................................................. 1724
Conclusion ............................................................................................................................................. 1725
Author contributions ............................................................................................................................... 1725
Funding .................................................................................................................................................. 1725
Competing interests ............................................................................................................................... 1725
Ethical approval ..................................................................................................................................... 1725
References ............................................................................................................................................... 1725

Introduction

The high degree of similarity between the host and the eukaryotic pathogen (fungus) often sets back the development of compounds against it. In addition, the fungus is still least considered an important pathogen by health officials and the public [1]. Booming counts of immunodeficient individuals have diverted attention to the mortal fungal afflictions as they spike the global health burden [2]. Currently, the whole world is tackling the holocaust of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and adding to the health hazard burden, a wide range of harmless fungal species are breaching the barriers and overwhelming the hospitals with a range of fungal sepsis in SARS CoV-2 infected or survivors. By far, >500 fungal species are known to infect humans with mild superficial sepsis to lethal invasive sepsis, mainly in immune deficit persons [3,4]. As of now, 233, 186, 5631 cases (according to worldometer.info) are battling with Coronavirus disease (COVID-19) around the globe and are administered with corticosteroids [Dexamethasone (DEX)] as therapeutic measures to downregulate the SARS CoV-2 viral replication and infectivity in the infected patients by modulating cytokines, majorly the interleukins (IL-1,4,6,8,12) and tumor necrosis factor (TNFα) [5]. Studies in 2008 by Zhang et al. [6] on the SARS animal model showed a decrease in the cytokines production of both innate (Interferons α and β) and Th1 cytokines (IL-1,4,6,8 & TNFα) in DEX treated animal model initially. However, long term use at a higher dose or prolonged usage exacerbates lung lesions with a significant increase in IL-4. In addition, hematolymphohistiocytosis syndrome along with COVID-19 are at higher risk to infect with invasive fungal infection due to immune modulation caused by both the SARS-CoV-2 and the corticosteroids used for treatment [7]. Similarly, studies by de León-Borrás and his colleagues pointed out the use of corticosteroids as treatment increases the risk of invasive fungal sepsis by 3.33 times than the patients receiving non-steroid treatments [8] (Fig. 1). We want to bring to notice the trauma observed in few COVID-19 survivors post SARS CoV-2 infection, specifically the fungal invasion through this narrative review.

First-hand sources

Talento and Hoenigl [9] through their editorial highlighted the occurrence of secondary fungal infections of *candida* and *Aspergillus* species as COVID-19-associated pulmonary aspergillosis (CAPA) and *candida* infections in blood due to tampered immune reac-
Fig. 1. Elucidates the effects induced by SARS-CoV-2 in the human host after its entry. The cytokine levels are zapped to cause Cytokine Storm Syndrome (CSS), namely the levels of pro-inflammatory cytokines are increased and anti-inflammatory cytokines are reduced leading to inflammation in the lungs and administering corticosteroids reduces the inflammations in the lungs initially. But the CSS in the body along with the corticosteroids actions makes the host more susceptible to get infected by the opportunistic fungi present inside and outside of the body to flourish in full swing. Which culminated into secondary invasive fungal infections like mucormycosis, yellow/green fungus or white fungus formation.

Fig. 2. The timeline of SARS-CoV-2 in the human host and the mechanism of interaction with corticosteroids to battle the COVID-19 infection. Blocking the immune cells helps the virion replicate and further disorganize the RAAS metabolism to worsen the conditions of succumbing to mechanical ventilation. Abbreviation: ARDS-Acute respiratory distress syndrome, ICU-Intensive care unit, IL-Interleukin, TNF-Tumor necrosis factor, RAAS-Renin-angiotensin-aldosterone system, ROS-Reactive oxygen species.

Cellular cells in the lungs damages the alveoli. It accumulates fluids full of proteins in the interstitium of the lungs, provoking the production of pro-inflammatory cytokines (IL-1,6,8, M1 macrophage, and TNF), causing neutrophil activation and release of toxic mediators such as reactive oxygen species as well as injuries in endothelial cells of capillaries and epithelial cells of alveoli. This situation leads to fibroblast multiplication producing fibrosis in the interstitial and intra-alveolar region followed by a need for ventilation via machines (MV) [18], as shown in Fig. 2.

Being parallel in pathology like ARDS, COVID-19 is also treated with corticosteroids. Administration of corticosteroids mainly depends on the timing, as early treatment elevates viral reproduction and postpones adaptive immunity. According to some studies, corticosteroids must be given at the pulmonary phase in COVID-19 pathology to obtain its benefit by declining the state of hyper inflammation [15,17,19]. Generally, the glucocorticoids and mineralocorticoid receptors are triggered by the corticosteroids to induce anti-inflammatory and hyperglycemia sequels along with
Corticosteroids endorsement for COVID-19

Apart from concomitant manifestations like ARDS, corticosteroids were not administered to COVID-19 cases. However, methylprednisolone has shown few positive observations in a Chinese study [20]. With randomized trials, the recommendations for corticosteroids were altered. Another recovery trial study carried out in the United Kingdom showed the utilization of DEX (6 mg/day) for 10 days or till discharge showed a reduction in mortality along with MV [21]. Use of systemic corticosteroids as amalgamation with antivirals and immune alternators like tocilizumab (Interleukin-6 inhibitor) and baricitinib (Kinase inhibitors) are shown to be effective in COVID-19 patients. Sometimes variation in duration and dosage of formulated systemic corticosteroids have shown benefits in patients from smaller randomized trails. Other Glucocorticoids like Hydrocortisone (160 mg), Prednisone (40 mg) and Methylprednisolone (32 mg) is recommended in the absence of DEX [22]. Additionally, corticosteroids with inhalation property like Budesonide is shown to impair virion replication plus downregulation of receptors of cellular entry [23]. According to the REACT group (World Health Organization’s rapid evidence appraisal for COVID-19 therapies), the mortality rate is reduced after the inclusion of corticosteroids rather than placebo and usual care in COVID-19 critical cases [24]. Hence, corticosteroids were commended to patients with pneumonia and the need for oxygen supplementation or ventilators. Not mandatory for cases without breathing difficulty.

Fungal blooms in severe COVID-19 cases

Using the approved corticosteroid level for a longer duration leads to fluid retentions in the body with swelling and weight gain plus diabetes-like conditions as plausible side effects in the patients [25]. In addition to mimicking natural products to reduce inflammation, corticosteroids are highly potent to reduce the normal functioning of the immune system in the body (Fig. 3). Likewise to attenuate the CRS anti-interleukin-6 (IL-6) therapy is given in COVID-19 cases, which can lead to adverse conditions as seen in mice models with lower or nil expression of IL-6. Since the mice loses it immunity against microbes specially like bacteria and fungus [26]. This situation allows opportunistic pathogens like fungi to bloom in full swing and the invasion of fungal sepsis is dependent on the host’s immune potency and the species of the fungi. In some cases, the probability of retriggering the dormant fungal spore is high under immune-compromised states, increasing the chances of invasive fungal infections in person. I CU COVID-19 patients, patients requiring MV and those who had longer stay in hospital were seen to be infected with fungus due to suppression of immunity in the patients due to extensive steroids and antibiotics administration of broad-spectrum [27]. To date, the ubiquitous fungal species like Mucorales, Aspergillus and Candida are seen to invade the immunity jeopardized COVID-19 survivors and cause infections mucormycosis (black fungus), green/yellow fungus and white fungus by taking advantage of their immune deficiency due to extensive treatment along with predisposing characters of diabetes ketoacidosis [28,29], and obesity as enlarged adipose tissues are apoptotic with immune cells attraction ability, causes inflammation by disorganizing the metabolic pathway of fatty acid [30].

Invasion of the Mucorales

Abridged scars on the skin, inhalation and taking in contaminated food are the entry point of Mucorales in a host body to infect the cutaneous, pulmonary, gastrointestinal and rhino-orbital or cerebrum region by rapidly invaginating in the blood vessels to cause thrombosis and dissemination, leading to necrosis of the tissue [19]. The endothelial and epithelial cells separated from stroma through the basement membrane constitute laminin and collagen IV extra-cellular proteins. The lining of epithelial cells is damaged usually during diabetes and extensive medications or ventilations process. Thus leading to the exposure of the proteins to directly interact with the surrounding fungal spores, and one of the most common mucorales genus Rhizopus binds with the collagen and laminin proteins using the endothelial glucose-regulator protein 78 (GRP 78) receptor Rhizopus endocytose itself inside the host and forms its hipe [29]. The GRP78 binding ligand belongs to the spore coating proteins family, universally seen only in Mucorales [31]. Collectively, the spore coating protein of the Mucorales and GRP78 of the host endothelium leads to invasive fungal sepsis.
In addition, the presence of diabetes and related ketoacidosis like conditions can further enhance the pathogenesis of the Rhizopus genus as the lower pH of blood, higher levels of glucose, iron and the β-hydroxybutyrate impairs chelation of iron from transferrin and acidic condition necessary for the growth of the fungus [29]. Huge number of cases were registered under mucormycosis associated with SARS-CoV-2 infection in COVID-19 patients in ICU’s or with mechanical ventilators in middle or later stage of the infections, with increased mortality and longer hospital stay with ventilators [32]. Recent review highlighted the prevalence rate of about 81.2% (82/101 cases) in India (80 times higher prevalence compared to whole world) with mortality of 30.7% [33]. Cases of mucormycosis was also registered without known risk factors suggesting the virion and the drugs administered could induce immune suppression, there by expose the patients to opportunistic fungus [34].

Candida albicans pathogenesis

Candida showcases dichotomous morphological form depending on the immune reactions of the host, the surroundings and its ability to transition from single-celled yeast to hyphae. Yeast is the commensal form causing infection circulation or disperse, and hyphae as the pathogenic infectious form can invaginate deeper in the tissues and destroy them [3]. The hyphae wall protein and agglutinin like sequence interact with the adhering host cell by dissolving the membranes through aspartic protease secretion [35]. These fungi evade immune cells by declining or blocking the pathogen-associated molecular patterns (PAMPs), lowering the fusion of phagosomes with lysosomes, declining opsonization, breaking down the complement factors or by releasing catalases and superoxide dismutases, reduce the concentrations of antimicrobial peptides, disturbing the balance between Th1 and 2 cells [3]. In addition, they also produce a toxin called Candidalysin capable of changing the membrane integrity in macrophages [36]. They can also trigger M1 macrophage differentiation into M2 to protect themselves and increase their livelihood [37]. Cohort studies on COVID-19 secondary infections has reported the presence of Candida infection in bloodstream in about 0.03–10% of COVID-19 patients admitted in the hospital with the invasion of the fungal after about 7 days of admission and show cases >850 mortality [38].

Aspergillus species mode of action

These species are rarely observed in immune-compromised persons, but they are quite morbid and mortal by increasing the susceptibility for mortality from 40 to 90% in immune deficit patients [3]. Through asexual reproduction, they produce conidiospores inhaled and engulfed in the macrophages of the alveolar region to trigger the pro-inflammatory reaction to recruit neutrophils at the site of infectivity in the immunity compromised persons. The spores trick macrophages and germinate by invaginating the vessels lumen through the cells in the epithelial and endothelial region [39]. Like Candida species, Aspergillus evade immune cells by blocking important PAMPs, the interaction between lysosome-phagosome, increasing the production of catalases capable of antioxidants, mannitol and SOD. Aspergillus produce secondary metabolic products like fumagillin, cytochalasin E, gliotoxin and actibind to express a wide range of immunocompromised reactions. Another quirky Aspergillus feature includes producing melanin pigments to protect its spores from environmental adversities outside the host. It helps in scavenging intermediates of reactive oxygen in the human cells and masking β-glucans and trafficking conidiospores intracellularly to cause infectivity [3]. Till date few hundreds of CAPA related mortality have been registered and studies showed the prevalence of 23.3%–34.4% in COVID-19 patients from asymptomatic to superinfection [40].

Communion of fungus and host

In general, the infection rate depends on the level of interaction between the pathogen and host; in this case, the PAMPs of the pathogen and the pathogen recognition receptors (PRRs) on the host initiate the immune response in the host. The diverse immune cells like polymorphic nuclear leukocytes, macrophages, dendritic cells and non-immune cells like fibroblast and epithelial cells of the host express the PRRs on their surfaces to tackle the pathogens. The usual PAMPs are glucans (α and β), mannans (N and O linked), peptidoglycan proteins, liposaccharides and phospholipomannan. These constitute the cell wall of fungus and are acknowledged by the highly conserved host PRRs like toll-like receptors (TLRs), C-type lectin receptors (CLRs) and oligomerization domains of nucleotide-binding like receptors (NLRs) (Table 1). Anti-fungal activity is actively carried out by TLRs (2,4,9) and CLR’s [3]. The complementary system of the host recognizes the mannanproteins of the fungal cell wall to cause phagocytosis or opsonization, followed by elevated production of antimicrobial peptides, cytokines and chemokines in the host. TLRs(2 and 4) recognize derivatives of mannann and lipomannan to induce Th1 and Treg cells [41]. Similarly, immune cells express miracle to ligate with the mannose of fungi and trigger the release of TNF α and IL-10. Being commensal fungi interact with a host by creating immune response tolerance; when the balance is distorted in an immune-deficient person, the infection spreads to various major organs [3].

Other persuasive entry routes of fungal spores in COVID patients or survivors

Considerably, fungal infection is observed in immunocompromised and people with comorbid predisposition like diabetic ketoacidosis with a 100% fatality rate in a severe infectious state. Primarily the ubiquitous spores enter through various routes like ingestion, inoculation in the injured region, inhalation. Apart from these, the fungal contamination in medical supplies like bandages, ostomy adhesive bags, linens [42] can also contribute to hospital outbreaks of invasive fungal growth in COVID patients undergoing treatment in hospitals. There is another possibility of inhalation spores during the hospitalization period; due to the immunosuppressive effects of the drugs administered to mitigate COVID, the individual can become a susceptible host after discharge from the hospital or while under surveillance due to higher iron levels in patient’s serum under COVID treatment or survivor. As already known, the spores’ viability depends on the suitable conditions, here iron supply makes them stay alive for a longer duration [29].

Reformed mycobiome in SARS CoV-2 infection

Apart from bacteria, the gastrointestinal track nurses some fungal species know as mycobiome to provide immunity alone with the other microbiota [43]. Studies by Zuo et al. [44] showed maladjustment in the alimentary track mycobiome of COVID-19 patients compared with healthy even on the last day of infection. They observed a heterogenous group of microbiome groups growing in the gut due to reduced T cells production in the host body due to SARS CoV-2 infection [45]. Reports show the presence of Candida and Aspergillus species in the faeces of COVID-19 patients, and there is a possibility of these fungal species at the post-recovery phase to trigger secondary infections like black and white, yellow or
green fungus in the COVID-19 survivors. In addition to the intestinal mycobiome, alteration in pulmonary mycobiome is also observed in pneumonia infections [44].

The above paragraphs highlight the mode of interaction, entry and the effects of the lesser considerate pathogen–fungus in COVID-19 patients and survivors. Immune cell malfunction triggers the catastrophic events in their pre and post COVID-19 phase due to the use of corticosteroids and anti-inflammatory drugs during the hospitalization period [11]. In addition, presence of comorbidity like diabetes, hypertension further adds up to the malaise. Revising the drug administration and checking the fungal markers in respiratory samples, body fluid can allow us to tackle it at its earliest [46]

Conclusion

Harmless fungus conquers the human body in an exclusively immune-suppressed state, i.e. when the defense mode is impeded. Hence making immune-suppressing drugs act as a two-sided sword used to treat the severe inflammatory condition with a sign of spiking the peril of exposing the host body to various infections. The rife COVID-19 mainly increases pro-inflammatory compounds' levels to cause cytokine storms, and immune suppressive drugs play a significant role in combating the pandemic. In addition, pneumonia and acute respiratory distress syndrome cause fungal concomitance by altering the gut and pulmonary mycobiome. Immune compromised condition is one of the prime predisposing features to harbor fungal sepsis of medical significance. The utilization of aggressive treatment methods, corticosteroids, antibiotics steeps down the immunity of the host against the invading fungus to comprehend its pathology leading to a morbid situation. The limitations of the current study includes the exclusion of other less frequent opportunistic fungus like Histoplasma sp., Cryptococcus sp., and Pneumocystis jirovecii in COVID-19 secondary infections and patients with pre-existing immune compromised states due to organ transplantations, hematological malignancies etc. Due to the scarcity of mycoses animal models, the anti-fungal effect of the host is lesser-known when compared with bacteria and viruses, as fungal sepsis is majorly seen in immune response jeopardized people. Proper guidelines are required to control the administration of drugs related to declining immunity in the COVID-19 cases, survivors and COVID-19 people with additional malaises like diabetes, inflammatory disorders and those undergoing chemotherapy or other treatments to identify the mycoses in the initial stages to increase their livelihood. More rigorous research must be done to refine the drug administration and management guidelines in patients/survivors of COVID-19, along with patients with other comorbidity plus COVID-19.

Author contributions

Conceptualization, G.D.R., A.M., and M.S.; Writing-original draft preparation, K.P., H.K., A.M., and B.B.; Literature search, selected bibliographic sources, B.B., V.T., A.A.R., M.P., K.P., A.M.A., R.M.A., and V.A.; Figures, H.K., and K.P. B.B and A.M were coordinated the working group; Supervision, Validation, Writing-review & editing, M.S., A.A.R., A.M.A., R.M.A., G.D.R., A.M., and H.K. All authors have read and agreed to the published version of the manuscript.

Funding

No funding sources.

Competing interests

None declared.

Ethical approval

Not required.

References

[1] Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl Trop Dis 2020;14(2):e0007964.
[2] Oliveira LVN, Wang R, Specht CA, Levitz SM. Vaccines for human fungal diseases: close but still a long way to go. npj Vaccines 2021;6(1):1–8.
[3] Pathakumari B, Liang G, Liu W. Immune defense to invasive fungal infections: a comprehensive review. 2020 https://pubmed.ncbi.nlm.nih.gov/32738740/.
[4] Kuchi Bhotta H, Balasubramanian B, Arumugam VA, Pushparaj K, Easwaran M, Baskaran R, et al. Insinuating cocktailed components in biocompatible-nanoparticles could act as an impressive neo-adjuvant strategy to combat COVID-19. Nat Resour Human Health 2021;1(1):3–7.
[5] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223):473–5.
[6] Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. Cytokeine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. J Virol 2008;82(9):4420–8.
[7] Sregelces-Calvo G, De Saraújo GR, Frases S. Systemic mycoses: a potential alert for complications in COVID-19 patients. 2020 https://pubmed.ncbi.nlm.nih.gov/33085538/.
[8] de León-Borrás R, DelPilar-Morales E, Rivera-Pérez N, Pallens-Feliciano M, Tirado-Gómez M, González-Sepúlveda L, et al. Factors associated to invasive fungal infection in Hispanic patients with hematological malignancies. Biotrop Med P R 2017;109(1):43–8.
[9] Talento AF, Hoenigl M. Fungal infections complicating COVID-19: with the rain comes the spores. J Fun1gi (Basel) 2020;6(4):1–2.
[10] Szarp Ł, Chirico F, Pruc M, Szarp Ł, Dzieciatkowski T, Rafique Z. Mucormycosis-a serious threat in the COVID-19 pandemic? J Infect 2021;83(2):237–9.
[11] Pushparaj K, Kuchi Bhotta H, Arumugam VA, Pappusamy M, Easwaran M, Liu W-C, et al. Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets-Magnifying global pandemic grief and catastrophe begins; 2021.
[12] McEwen BS, Biron CA, Bronson KW, Bulloch K, Chambers WH, Dhabhar FS, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions; 1997 https://pubmed.ncbi.nlm.nih.gov/9063588/.
[13] Youssuf J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use; 2016 https://pubmed.ncbi.nlm.nih.gov/26611557/.
[14] Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights; 2011 https://pubmed.ncbi.nlm.nih.gov/20398732/.
[15] Siddiqi HK, Meher MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405.
[16] Bhotta HK, Kaul T, Balasubramanian E, Easwaran M, Arumugam VA, Pappusamy M, et al. Platelets to surrogage lung inflammation in COVID-19 patients. Med Hypotheses 2020;143:110098.
[17] Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55(5).

[18] Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med 2017;377(6):562–72.

[19] Williams DM. Clinical pharmacology of corticosteroids. Respir Care 2018;63(6):655–70.

[20] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):924–43.

[21] Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384(8):693–704.

[22] The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324(13):1330–41.

[23] Matsuyma S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol 2020;95(1).

[24] Sterne JC, Murphy S, Biax J, Slutskiy AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324(13):1330–41.

[25] Brenner EJ, Ungaro RC, Garry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159(2):481–91.e3.

[26] Kimming LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med 2020;7:583897.

[27] Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. 2020 https://pubmed.ncbi.nlm.nih.gov/32737747/.

[28] Puebla LE. Fungal infections in immunosuppressed patients. Immunodeficiency 2012.

[29] Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis—the bitter and the sweet. PLoS Pathog 2017;13(8).

[30] Mohammad S, Aziz R, Al Mahri S, Malik SS, Haji E, Khan AH, et al. Obesity and COVID-19: what makes obese host so vulnerable? 2021 https://pubmed.ncbi.nlm.nih.gov/33390183/.

[31] Gehemaratham T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 2014;124(1):237–50.

[32] Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. 2020 https://pubmed.ncbi.nlm.nih.gov/32737747/.

[33] Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev 2021;15(4):102146.

[34] Pemán J, Ruiz-Gaitán A, García-Vidal C, Salavert M, Ramírez P, Puchades F, et al. Fungal co-infection in COVID-19 patients: should we be concerned? 2020 https://pubmed.ncbi.nlm.nih.gov/33041191/.

[35] Naglik JR, Moyes DL, Wachtler B, Hube B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect 2011;13(12–13):963.

[36] Kasper L, Franke A, Mogavero S, Hoefs S, Martin R, Wilson DW, et al. Role of the fungal peptide toxin Candidalysin in macrophage damage and inflammatory response. Mycoses 2016;59:1–9.

[37] Reales-Calderón JA, Aguiler-Montilla N, Corbi ÁL, Moleró C, Gil C. Proteomic characterization of human proinflammatory M1 and anti-inflammatory M2 macrophages and their response to Candida albicans. Proteomics 2014;14(12):1503–18.

[38] Churilo M, Manstrangelo A, Ripa M, Scarpellini P. Invasive fungal infections in patients with COVID-19: a review on pathogenesis, epidemiology, clinical features, treatment, and outcomes. New Microbiol 2021;44(2):71–83.

[39] Amitani R, Murayama T, Nawada R, Lee WJ, Niimi A, Suzuki K, et al. Aspergillus culture filtrates and sputum solids from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Eur Respir J 1995;8(10):1681–7.

[40] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–33.

[41] Brouwer N, Dolman KM, van Hout M, Sta M, Roos D, Kuipers TW. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008;180(6):4124–12.

[42] Duffy J, Harris J, Gade L, Schulster L, Newhouse E, O’Connell H, et al. Mucormycosis outbreak associated with hospital linens. Pediatr Infect Dis J 2014;33(5):472–6.

[43] van Tilburg Bernardes E, Pettersen VK, Guitierrez MW, Laforest-Lapointe I, Jendzjowsky NG, Cavin J-B, et al. Invasive fungi are causally implicated in microbiome assembly and immune development in mice. Nat Commun 2020;11(1):1–16.

[44] Zuo T, Zhan H, Zhang F, Liu Q, Tsu EYK, Lui GYC, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology 2020;159(4):1302.

[45] Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020;0:827.

[46] Pasero D, Sanna S, Liperi C, Pireddà D, Pietro Branca G, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection 2020;48(5).